Show simple item record

dc.contributor.authorChamakh-Ayari, Rym
dc.contributor.authorBras-Gonçalves, Rachel
dc.contributor.authorBahi-Jaber, Narges
dc.contributor.authorPetitdidier, Elodie
dc.contributor.authorMarkikou-Ouni, Wafa
dc.contributor.authorAoun, Karim
dc.contributor.authorMoreno, Javier 
dc.contributor.authorCarrillo, Eugenia 
dc.contributor.authorSalotra, Poonam
dc.contributor.authorKaushal, Himanshu
dc.contributor.authorNegi, Narender Singh
dc.contributor.authorArevalo, Jorge
dc.contributor.authorFalconi-Agapito, Francesca
dc.contributor.authorPrivat, Angela
dc.contributor.authorCruz, Maria
dc.contributor.authorPagniez, Julie
dc.contributor.authorPapierok, Gérard-Marie
dc.contributor.authorRhouma, Faten Bel Haj
dc.contributor.authorTorres, Pilar
dc.contributor.authorLemesre, Jean-Loup
dc.contributor.authorChenik, Mehdi
dc.contributor.authorMeddeb-Garnaoui, Amel
dc.date.accessioned2018-12-18T14:28:16Z
dc.date.available2018-12-18T14:28:16Z
dc.date.issued2014-05-02
dc.identifier.citationPLoS One. 2014 May 2;9(5):e92708es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6888
dc.description.abstractPSA (Promastigote Surface Antigen) belongs to a family of membrane-bound and secreted proteins present in several Leishmania (L.) species. PSA is recognized by human Th1 cells and provides a high degree of protection in vaccinated mice. We evaluated humoral and cellular immune responses induced by a L. amazonensis PSA protein (LaPSA-38S) produced in a L. tarentolae expression system. This was done in individuals cured of cutaneous leishmaniasis due to L. major (CCLm) or L. braziliensis (CCLb) or visceral leishmaniasis due to L. donovani (CVLd) and in healthy individuals. Healthy individuals were subdivided into immune (HHR-Lm and HHR-Li: Healthy High Responders living in an endemic area for L. major or L. infantum infection) or non immune/naive individuals (HLR: Healthy Low Responders), depending on whether they produce high or low levels of IFN-γ in response to Leishmania soluble antigen. Low levels of total IgG antibodies to LaPSA-38S were detected in sera from the studied groups. Interestingly, LaPSA-38S induced specific and significant levels of IFN-γ, granzyme B and IL-10 in CCLm, HHR-Lm and HHR-Li groups, with HHR-Li group producing TNF-α in more. No significant cytokine response was observed in individuals immune to L. braziliensis or L. donovani infection. Phenotypic analysis showed a significant increase in CD4+ T cells producing IFN-γ after LaPSA-38S stimulation, in CCLm. A high positive correlation was observed between the percentage of IFN-γ-producing CD4+ T cells and the released IFN-γ. We showed that the LaPSA-38S protein was able to induce a mixed Th1 and Th2/Treg cytokine response in individuals with immunity to L. major or L. infantum infection indicating that it may be exploited as a vaccine candidate. We also showed, to our knowledge for the first time, the capacity of Leishmania PSA protein to induce granzyme B production in humans with immunity to L. major and L. infantum infection.es_ES
dc.description.sponsorshipThis study received financial support from EU's Seventh Framework Programme (FP7) (RAPSODI project, grant agreement number 223341).es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdaptive Immunity es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAntigens, Protozoan es_ES
dc.subject.meshAntigens, Surface es_ES
dc.subject.meshGranzymes es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunity, Humoral es_ES
dc.subject.meshInterferon-gamma es_ES
dc.subject.meshInterleukin-10 es_ES
dc.subject.meshLeishmania es_ES
dc.subject.meshLeishmaniasis es_ES
dc.subject.meshMice es_ES
dc.subject.meshPhenotype es_ES
dc.subject.meshProtozoan Vaccines es_ES
dc.subject.meshSolubility es_ES
dc.subject.meshTumor Necrosis Factor-alpha es_ES
dc.titleIn vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasises_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID24786587es_ES
dc.format.volume9es_ES
dc.format.number5es_ES
dc.format.pagee92708es_ES
dc.identifier.doi10.1371/journal.pone.0092708es_ES
dc.contributor.funderUnión Europea. Comisión Europea. 7 Programa Marco 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1932-6203es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0092708es_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/223341/EUes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional